Where AI helps — and doesn't — in drug discovery

Martin Shkreli is the co-founder of DL Software, the parent company of Godel Terminal, a Bloomberg competitor for financial data. He previously founded the biotech companies Retrophin and Turing Pharmaceuticals and the hedge fund MSMB Capital Management. 

In this episode of Summation, Martin and Auren discuss:

• The structural reasons fintech is less competitive than other industries
• How drug discovery actually works (and doing it from prison)
• Why AI labs are now out-recruiting hedge funds
• What Martin learned from being "the most hated man in America"

You can find Auren Hoffman on X at @auren and Martin Shkreli on X at @MartinShkreli